If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today. By David Jagielski – Aug 11, 2023 at 8:25AM Key Points. Viatris is a ...

Additionally, Viatris lowered its guidance for 2025, projecting total revenues between $13.5 billion and $14 billion. As a result, VTRS shares plummeted 15.2% after the quarter earnings release.

Viatris performance has remained lackluster over the longer term as well. VTRS stock has plummeted 28.9% on a YTD basis and 15.5% over the past 52 weeks, notably underperforming SPX’s 2.4% ...

Generic drugmaker Viatris has convinced a federal judge in West Virginia that its proposed generic version of a Johnson & Johnson unit's cardiovascular drug Veletri would not infringe J&J's ...

With a market cap of $10.2 billion, Viatris Inc. (VTRS) operates as a healthcare company in North America and internationally. Founded in 1961, the Canonsburg, Pennsylvania-based company operates ...

Viatris (VTRS 0.57%) makes both generic and branded drugs and its stock looks like a potential steal of a deal at the moment. It trades at less than 6 times its earnings, and it pays a dividend ...

Viatris Inc.'s Q1 2025 earnings show declining revenues and profits, yet the stock rose nearly 10% due to stable full-year guidance and positive pipeline updates. The company's significant debt ...

So, Viatris' revenue for the fourth quarter of 2023 is anticipated to be in the range of $3.78 billion to $3.98 billion, which is 0.1% less than the previous year.

J&J first sued Viatris—at the time still Mylan—back in September 2020 after the company sought approval for generic versions of Invega Trinza’s 546-mg dose.

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic ...

Viatris is ponying up $25 million upfront to obtain the rights to sell Lexicon Pharmaceuticals’ SGLT1/SGLT2 heart med sotagliflozin, known commercially as Inpefa, in all global markets beyond ...

Viatris (NASDAQ: VTRS) spun off from Pfizer and merged with Mylan back in 2020. It's a generic drugmaker with a diverse, global business that serves patients and customers in over 165 countries ...